About the Biogen Hemophilia New Company Spin-off Plans
Biogen has announced plans to spin off a separate company focused on the needs of people living with hemophilia and the physicians, scientists and other allied care professionals who provide treatment. The new company will provide ALPROLIX®[Coagulation Factor IX (Recombinant), Fc Fusion Protein] and ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] to people living with hemophilia, and research new treatments, including gene therapies.
Below are answers to a few questions you may be wondering about. Should you have additional questions about this news, please contact your local Biogen CoRe Manager.
If I am, or my family member is, currently on a Biogen product, will I still be able to receive the therapy as usual?
This plan is not expected to have any impact on the manufacture or availability of the medicines you rely on. Biogen will continue to manufacture ELOCTATE and ALPROLIX and is committed to manufacturing excellence and maintaining a sufficient product supply. You should continue to expect that your medicines will be available via the same channels through which you currently receive them.
Will Biogen products still be available once the new company is fully formed?
- Once the transition to the new company is complete, your medicines will be available through that company. We expect that this transition will be completed by the end of 2016 or early 2017.
I currently have a support relationship with a Biogen CoRe or representative. Will I still be able to speak with them?
- The plan is for people who you work with at Biogen on a day-to-day basis to move to the new company.
Will there be any changes to the Biogen patient services program?
- You should continue to expect that your medicines will be available via the same channels through which you currently receive them. As always, don't hesitate to contact your CoRe Manager with questions or for additional resources.
Will key programs that Biogen has committed to continue on as planned?
- The new company will continue Biogenís 10-year commitment to donating up to 1 billion international units of clotting factor for Humanitarian Aid, to close the treatment gap in developing nations. In the United States, the new company is expected to continue Biogenís support of the My Life, Our Future program Ė in partnership with the American Thrombosis and Hemostasis Network, the National Hemophilia Foundation and Bloodworks Northwest Ė a nationwide campaign to offer a free genotyping test, to enable a deeper understanding of hemophilia and to help advance the breakthrough treatments.
What made Biogen decide to create a separate company for their hemophilia medicines?
- By creating two distinct businesses, Biogen sees an exciting opportunity to enable each to build upon their own unique strengths and lead in their respective areas of focus. The new company will continue to engage with and invest in the hemophilia community, provide ALPROLIX and ELOCTATE, and continue developing and researching new treatments for hemophilia, including gene therapies. Biogen believes this new enterprise will further accelerate innovation for people living with hemophilia, building on Biogenís work that recently brought the first new treatment options to the hemophilia community in nearly two decades.
What is the new company called and when will it be official? Is there any other information about the new company to know about at this time?
- The new company will be named at a later date, and is expected to be headquartered in the Boston area. The spin-off is expected to be completed by the end of 2016 or early 2017.